title: P2U agonists induce chemotaxis and actin polymerization in human neutrophils and differentiated HL60 cells.
abstract: Human neutrophils or HL60 cells express P2U receptors and respond to micromolar concentrations of ATP, adenosine 5'-O-(thiotriphosphate) (ATPgammaS), or UTP with immediate increases in intracellular Ca2+ through activation of phosphoinositide phospholipase C (Cowen, D. S., Lazarus, H. M., Shurin, S. B., Stoll, S. E., and Dubyak, G. R. (1989) J. Clin. Invest. 83, 1651-1660). P2U agonists reportedly induce limited enzyme secretion and enhance the respiratory burst in response to chemotactic factors. We demonstrate here that P2U agonists are chemotactic for neutrophils or differentiated HL60 cells. Rhodamine phalloidin staining indicates that ATPgammaS treatment induces actin polymerization and shape changes similar to those seen when these cells are treated with chemotactic peptide fMet-Leu-Phe. Although undifferentiated HL60 cells fail to mount a rise in Ca2+ when challenged with fMet-Leu-Phe, they increase Ca2+ in response to P2U agonists. However, functional expression of phospholipase C-coupled receptors is not sufficient for chemotaxis since HL60 cell migration in response to these agonists or to fMet-Leu-Phe occurs only after exposure to differentiating agents such as BT2cAMP. In addition to the well known G protein-linked receptors for lipid or peptide chemotactic factors, neutrophils apparently also can utilize G protein-linked purino/pyrimidino receptors to recognize nucleotides as chemoattractants. High concentrations of ATP and UTP generated at sites of platelet aggregation and tissue injury could thus be important mediators of inflammation.
authors.affiliation: Department of Cell Biology, Glaxo Wellcome Inc., Research Triangle Park, North Carolina 27709, USA.
authors.forename: M W
authors.initials: MW
authors.lastname: Verghese
authors.forename: T B
authors.initials: TB
authors.lastname: Kneisler
authors.forename: J A
authors.initials: JA
authors.lastname: Boucheron
mesh_terms: D008841:Actin Cytoskeleton / Q000502:physiology; D000199:Actins / Q000502:physiology*; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000595:Amino Acid Sequence; D002118:Calcium / Q000502:physiology; D002454:Cell Differentiation; D002630:Chemotactic Factors / Q000494:pharmacology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D018922:HL-60 Cells / Q000166:cytology*; D006801:Humans; D008969:Molecular Sequence Data; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000166:cytology*; D011108:Polymers; D011685:Purine Nucleotides / Q000494:pharmacology; D058910:Purinergic P2 Receptor Agonists; D058473:Receptors, Purinergic P2Y2; D015398:Signal Transduction; D014544:Uridine Triphosphate / Q000494:pharmacology
chemical_list: D000199:Actins; D002630:Chemotactic Factors; C546385:P2RY2 protein, human; D011108:Polymers; D011685:Purine Nucleotides; D058910:Purinergic P2 Receptor Agonists; D058473:Receptors, Purinergic P2Y2; C022571:adenosine 5'-O-(3-thiotriphosphate); D009240:N-Formylmethionine Leucyl-Phenylalanine; D000255:Adenosine Triphosphate; D002118:Calcium; D014544:Uridine Triphosphate